Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPTNASDAQ:AUPHNASDAQ:BGMNYSE:PBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$10.47+3.3%$8.92$2.99▼$10.87$1.54B1.81.57 million shs2.89 million shsAUPHAurinia Pharmaceuticals$7.92+0.1%$8.01$5.20▼$10.67$1.07B1.151.33 million shs1.05 million shsBGMBGM Group$12.97+2.5%$12.25$5.26▼$17.17$1.23B1.3831,259 shs115,790 shsPBHPrestige Consumer Healthcare$83.51-0.2%$83.85$64.63▼$90.04$4.14B0.45300,438 shs361,903 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.46%-3.06%+12.04%+34.13%+222.93%AUPHAurinia Pharmaceuticals-2.83%-2.94%-3.42%-5.50%+42.78%BGMBGM Group-10.28%-22.68%+0.88%+24.88%+1,264,999,900.00%PBHPrestige Consumer Healthcare-0.06%-3.43%-6.30%-0.11%+28.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies2.8277 of 5 stars1.41.00.04.22.92.50.6AUPHAurinia Pharmaceuticals3.1565 of 5 stars3.52.00.00.03.40.81.9BGMBGM GroupN/AN/AN/AN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare3.5002 of 5 stars2.32.00.03.51.51.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.86Moderate Buy$10.570.97% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5045.20% UpsideBGMBGM Group 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3311.76% UpsideCurrent Analyst Ratings BreakdownLatest PBH, AUPH, ADPT, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ADPTAdaptive BiotechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.005/5/2025ADPTAdaptive BiotechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.005/2/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.003/21/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.00 ➝ $9.003/21/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$96.00 ➝ $97.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M8.89N/AN/A$1.37 per share7.64AUPHAurinia Pharmaceuticals$235.13M4.55$0.31 per share25.65$2.68 per share2.96BGMBGM Group$25.10M50.24N/AN/A$7.34 per share1.77PBHPrestige Consumer Healthcare$1.14B3.63$5.20 per share16.05$37.04 per share2.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%7/30/2025 (Estimated)AUPHAurinia Pharmaceuticals$5.75M$0.2828.2914.14N/A16.11%14.27%9.93%7/30/2025 (Estimated)BGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$214.60M$4.2919.4717.542.5118.86%12.87%6.78%8/6/2025 (Estimated)Latest PBH, AUPH, ADPT, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ABGMBGM GroupN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.922.82AUPHAurinia Pharmaceuticals0.165.935.26BGMBGM GroupN/A3.392.82PBHPrestige Consumer Healthcare0.554.202.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%AUPHAurinia Pharmaceuticals36.83%BGMBGM GroupN/APBHPrestige Consumer Healthcare99.95%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%AUPHAurinia Pharmaceuticals12.20%BGMBGM Group58.66%PBHPrestige Consumer Healthcare1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million142.19 millionOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableBGMBGM Group29897.22 million40.19 millionN/APBHPrestige Consumer Healthcare54049.42 million48.62 millionOptionablePBH, AUPH, ADPT, and BGM HeadlinesRecent News About These CompaniesZacks Research Issues Positive Estimate for PBH EarningsJune 18 at 7:33 AM | marketbeat.comMedtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial ContaminationJune 17 at 5:38 PM | globenewswire.com7,572 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Bought by NorthCrest Asset Manangement LLCJune 15 at 4:49 AM | marketbeat.comShould You Continue to Hold Prestige Consumer Stock in Your Portfolio?June 11, 2025 | zacks.comWedge Capital Management L L P NC Trims Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 10, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and ...June 9, 2025 | gurufocus.comPrestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce ConferenceJune 9, 2025 | globenewswire.comOlstein Capital Management L.P. Sells 11,000 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 9, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Holdings Lowered by Rhumbline AdvisersJune 9, 2025 | marketbeat.comMillennium Management LLC Trims Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 8, 2025 | marketbeat.comCongress Asset Management Co. Buys 82,838 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 7, 2025 | marketbeat.comGAMMA Investing LLC Acquires 160,155 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 7, 2025 | marketbeat.comWellington Management Group LLP Has $1.77 Million Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 6, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 2, 2025 | marketbeat.comZacks Research Issues Optimistic Outlook for PBH EarningsJune 2, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $7.78 Million in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 1, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 23,334 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 1, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Position Lessened by Squarepoint Ops LLCJune 1, 2025 | marketbeat.comZacks Research Issues Positive Forecast for PBH EarningsMay 31, 2025 | marketbeat.comPBH vs. SYK: Which Stock Is the Better Value Option?May 30, 2025 | zacks.comCetera Investment Advisers Invests $413,000 in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBH, AUPH, ADPT, and BGM Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$10.47 +0.33 (+3.25%) Closing price 04:00 PM EasternExtended Trading$10.44 -0.03 (-0.29%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Aurinia Pharmaceuticals NASDAQ:AUPH$7.92 +0.01 (+0.13%) Closing price 04:00 PM EasternExtended Trading$7.98 +0.07 (+0.82%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.BGM Group NASDAQ:BGM$12.97 +0.32 (+2.53%) Closing price 04:00 PM EasternExtended Trading$12.96 -0.01 (-0.04%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Prestige Consumer Healthcare NYSE:PBH$83.51 -0.17 (-0.20%) Closing price 03:59 PM EasternExtended Trading$83.75 +0.23 (+0.28%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
